Wet Age-Related Macular Degeneration
A Phase I Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular Age-Related Macular Degeneration
A Phase III Randomized, Double-masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity Between SB11 and Lucentis® in Subjects With Neovascular Age-related Macular Degeneration
A Phase II, Multi-Center, Randomized, Double Masked and Active Controlled Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in combination with Lucentis® Compared to Lucentis® Monotherapy in Subjects with Wet AMD
A Phase I/Ib Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study To Evaluate The Efficacy And Safety Of Faricimab In Patients With Neovascular Age-Related Macular Degeneration
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age related Macular Degeneration (nAMD)
A multi-center, non-randomized, open-label, multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ro7200394 following intravitreal administration in patients with neovascular age-related macular degeneration
A multi-center, non-randomized, open-label, multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ro7200394 following intravitreal administration in patients with neovascular age-related macular degeneration
A phase IIIb/IV, multicenter, open-label, single-arm study of the efficacy and safety of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration previously treated with intravitreal agents other than ranibizumab
Serum Anti-AAV8 Neutralizing Antibody Assessment Study of Patients with Neovascular Age-related Macular Degeneration or Diabetic Retinopathy
A Phase 2, Randomized, Dose-escalation, Ranibizumab-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered Via One or Two Suprachoroidal Space (SCS) Injections in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
A Phase 2, Open-label Study to Explore the Pharmacodynamics of Two Doses in Two Formulations of RGX-314 Gene Therapy Administered Via Subretinal Delivery in Participants With Neovascular Age-related Macular Degeneration
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD
A Prospective, Multi-Center, Open-label, Sequential, Multiple Ascending-Dose and Randomized, Double-Masked Dose-Expansion Cohorts Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AM712 Following Intravitreal Administration in Patients With Neovascular Age-related Macular Degeneration
Open-label, Dose-escalation, Phase 1/2a Study of the Safety and Tolerability of Suprachoroidally Administered CLS-AX Following Intravitreal Anti-VEGF Therapy in Subjects With Neovascular Age-related Macular Degeneration
A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients With Neovascular AMD
Dry Age-Related Macular Degeneration
A Phase II/III Randomized, Double Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura® (Anti-C5 Aptamer) in Subjects with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
A Phase II, Open-Label, Outcomes-Assessor Masked, Multicentre, Randomised, Controlled Study To Evaluate The Safety And Efficacy Of Two Doses Of GT005 Administered As A Single Subretinal Injection In Subjects With Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration
A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
A Phase II, multicenter, randomized, single-masked, sham injection controlled study of the safety, tolerability, and evidence of activity of intravitreal injection of RO7171009 in patients with Geographic Atrophy secondary to age-related macular degeneration
A Phase 2, outcomes assessor-masked, multicentre, randomized study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration
A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Diabetic Macular Edema
A Phase I/Ib Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator Controlled Study To Evaluate The Efficacy And Safety Of RO6867461 In Patients With [both previously treated and treatment naïve] DME
A Prospective, Randomized, Double-Masked, Active Comparator-controlled, Multi-center, Two-arm, Phase III Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME)
A Randomized, Double-Masked, Active-Controlled Phase 2/3 study of the Efficacy and Safety of High-Dose Aflibercept in patients with Diabetic Macular Edema
A Phase III, Three-Arm, Randomized, Double-Masked, Multicenter Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to DME
A Phase II, Multicenter, Randomized, Double Masked, Active Comparator-Controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200220 in Combination With Ranibizumab Administered Intravitreally in Patients With Diabetic Macular Edema
A phase II, multicenter, randomized, double masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7200220 administered intravitreally in patients with diabetic macula
A Randomized, Masked, Controlled Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
A longitudinal, biomarker study of anti-VEGF, to explore the relationship between aqueous humor composition and multimodal retinal imaging in neovascular age-related macular degeneration and diabetic macular edema
A Phase 2, randomised, single-masked, active controlled, multicentre study to evaluate the efficacy and safety of THR-149 for the treatment of diabetic macular oedema (DME)
A phase IIIb/IV, multicenter, open-label, single-arm study to investigate faricimab (Ro6867461) treatment response in treatment-naïve, underrepresented patients with diabetic macular edema
Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema
Diabetic Retinopathy
A Phase II Randomized, Open Label Study to Evaluate Safety of Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement
Peripheral Diabetic Retinopathy (DR)Lesions on Ultrawide-field Fundus Images and Risk of DR Worsening Over Time
Treatment for Central-Involved Diabetic Macular Edema in Eyes With Very Good Visual Acuity
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
A Prospective, Randomized, Double-masked, Sham-controlled, Multicenter, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)
A multi-center, randomized, double-masked, 40-week, parallel group, placebo-controlled proof of concept study to investigate the efficacy and safety of RO6868847 in individuals with diabetes mellitus type 1 or Type 2 with treatment naïve diabetic retinopathy (DR)
A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening
Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema
A First-in Human trial to study safety and tolerability of single rising intravitreal dOses (open label, non-randomized, uncontrolled) and in addition the early biological response of multiple rising intravitReal doses (single-masked, raNdomized, sham-controlled) of BI 764524 in panretinaLphotocoagulation (PRP) treated proLiferative diabetic retinopathy (PDR) patients with diabetic macular ischemia (DMI)
A First-in Human trial to study safety and tolerability of single rising intravitreal doses (open label, non-randomized, uncontrolled) and in addition the early biological response of multiple intravitreal doses (single-masked, randomized, sham controlled) of BI 765128 in panretinal photocoagulation (PRP) treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischemia (DMI)
Retinal Vein Occlusion
A Phase I/Ib Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)
A Phase II, Multicenter, Open-label, Safety and Proof-of-concept Study to Assess Safety, Tolerability and Efficacy of AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
Nevus/Melanoma
Phase 1b Open-Label, single ascending dose clinical trial designed to evaluate the safety of two dose levels of light-activated AU-011-101 for the treatment of subject with small to medium (2.0mm-3.4mm thickness) primary choroidal melanoma
Identification of Germline BAP1 Mutation In Subjects With Choroidal Nevi or Uveal Melanoma
Radiation Retinopathy
The ARRT trial will assess the safety and efficacy of 2mg IAI for the treatment of radiation retinopathy, including maculopathy and optic neuropathy
Non-proliferative Diabetic Retinopathy
A Phase IIa Randomized, Double-masked, Placebo-controlled Exploratory Study to Evaluate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Orally Administered BI 1467335 for 12 Weeks with a 12-Week Follow Up Period in Patients with Non-Proliferative Diabetic Retinopathy without center-involved Diabetic Macular Edema
Macular Telangiectasia
A natural history observation and registry study of macular telangiectasia type 2 the Mactel study
Uveitis
ADalimumab Vs. conventional ImmunoSupprEssion for corticosteroid-sparing (ADVISE) Trial
A Phase III, Multicenter, Sham-Controlled, Randomized, Double-Masked Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
Retinitis Pigmentosa
Phase 3 Study of AAV2/5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene
